Publications associées à Pharmaceutical marketing

Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates

Grégoire Courtine, Quentin Barraud, Lili Huang, Xiaomeng Zhang

Spinal cord injury (SCI) is a devastating condition characterized by loss of function, secondary to damaged spinal neurons, disrupted axonal connections, and myelin loss. Spontaneous recovery is limited, and there are no approved pharmaceutical treatments ...

2021

Advancing Drug Discovery via Artificial Intelligence

Horst Vogel, Shuguang Yuan, Thamani Dahoun

Drug discovery and development are among the most important translational science activities that contribute to human health and wellbeing. However, the development of a new drug is a very complex, expensive, and long process which typically costs 2.6 bill ...

ELSEVIER SCIENCE LONDON2019

Latest advances in aging research and drug discovery

Andrea Ablasser

An increasing aging population poses a significant challenge to societies worldwide. A better understanding of the molecular, cellular, organ, tissue, physiological, psychological, and even sociological changes that occur with aging is needed in order to t ...

IMPACT JOURNALS LLC2019

Nanoparticle-Enhanced Plasmonic Biosensor for Digital Biomarker Detection in a Microarray

Hatice Altug, Alexander Belushkin, Filiz Yesilköy

Nanoplasmonic devices have become a paradigm for biomolecular detection enabled by enhanced light–matter interactions in the fields from biological and pharmaceutical research to medical diagnostics and global health. In this work, we present a bright-fiel ...

2018

Building up Resilience in a Pharmaceutical Supply Chain through Inventory, Dual Sourcing and Agility Capacity

Ralf Seifert, Florian Christopher Matthias Lücker

This paper is inspired by a risk management problem faced by a leading pharmaceutical company. Key operational risk mitigation measures include Risk Mitigation Inventory (RMI), Dual Sourcing and Agility Capacity. We study the relationship between these thr ...

2017

Real-time binding kinetics of ligand-receptor interactions : development and application of a label-free optical biosensor for living bacteria

Ekaterina Rostova

In principle, a major goal in drug development is to design a high-affinity compound with an appropriate pharmacological response, which requires understanding of physical processes underlying the drug-target interaction, affinity and specificity. This dru ...

EPFL2017

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

Pierre Vogel, Somi Reddy Majjigapu

Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies. Many novel IDO1 inhibitor scaffolds h ...

Amer Chemical Soc2015

Improving Risk Regulation

Marie-Valentine Renée Agnès Florin

Confronted with the challenge of improving regulatory performance, many governments in the world are looking for ways to better manage risks, in particular those risks that develop in complex systems, with stakeholders from various sectors, and that are ma ...

International Risk Governance Council (IRGC)2015

Life Cycle Analysis within Pharmaceutical Process Optimization and Intensification: Case Study of Active Pharmaceutical Ingredient Production

Lioubov Kiwi, Charline Berguerand

As the demand for new drugs is rising, the pharmaceutical industry faces the quest of shortening development time, and thus, reducing the time to market. Environmental aspects typically still play a minor role within the early phase of process development. ...

Wiley-VCH Verlag Berlin2014

Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells

Patrick Fraering

The goal of targeted cancer therapies is to specifically block oncogenic signalling, thus maximising efficacy, while reducing side-effects to patients. The gamma-secretase (GS) complex is an attractive therapeutic target in haematological malignancies and ...

Springer2014

Sensing hydrogen peroxide by carbon nanotube/horseradish peroxidase bio-nanocomposite

László Forró, Arnaud Magrez, Endre Horvath, Klara Hernadi

H2O2 is a product of reactions catalysed by several oxidase enzymes and it is essential in environmental and pharmaceutical analyses. The most commonly used enzyme in understanding the biological behaviour of catalysed oxidation of H2O2 is horseradish pero ...

Wiley-V C H Verlag Gmbh2013

Substance flow analysis as a tool for mitigating the impact of pharmaceuticals on the aquatic system

Luca Rossi, Sylvain Coutu, Jonas Margot, Htet Kyi Wynn

Pharmaceuticals constitute an important environmental issue for receiving waters. A holistic approach, taking into consideration the sources of these compounds (hospitals, domestic use), discharges (wastewater effluent, combined sewer overflows) and relate ...

Elsevier2013

Detection of Drug-Protein Interactions with an Improved Yeast Three-Hybrid System

Cindy Fellay

The identification of the targets of therapeutic drugs is one of the major challenges for pharmaceutical companies. The main target responsible for drug action is often known, but most drugs also bind other targets, either causing deleterious side effects ...

EPFL2013

Methodology to account for uncertainties and tradeoffs in pharmaceutical environmental hazard assessment

David Andrew Barry, Luca Rossi, Sylvain Coutu

Many pharmaceutical products find their way into receiving waters, giving rise to concerns regarding their environmental impact. A procedure was proposed that enables ranking of the hazard to aquatic species and human health due to such products. In the pr ...

Elsevier2012

Engineering Erythrocyte Affinity for Improved Pharmacokinetics and Immune Tolerogenesis

Stephane Kontos

The clinical success of recombinant protein therapeutics in the treatment of disease is a hallmark of modern medical research, yet there remain numerous unaddressed issues regarding their delivery and immunogenicity. Regardless of in vivo efficacy, the bio ...

EPFL2011

Removal of pharmaceuticals from water: Using liquid-core microcapsules as a novel approach

Urs von Stockar, Ian William Marison

In recent years ever-increasing amounts of pharmaceuticals are being detected in the aquatic environment and in some cases, they have even been discovered in drinking water. Their presence is attributed mainly to the inability of sewage treatment plants to ...

2010

Peptide ligands for targeting and retention of nanoparticles and protein therapeutics in articular cartilage

Dominique André Rothenfluh

Osteoarthritis (OA) is one of the most common causes of pain and disability. Currently, non-surgical treatment is limited to analgesic and anti-inflammatory drugs, which are not capable of either modifying the disease process or regenerate damaged parts in ...

EPFL2009

Fluoronaphthalene building blocks via arynes: A solution to the problem of positional selectivity

Eric Masson

When 3-fluoro- and 3-chloro-1,2-didehydrobenzenes are generated in the presence of 2-(trimethylsilyl)furan, two regioisomeric cycloadducts are formed in a 1:2 ratio. However, regioselectivity can be installed by fitting one bulky trimethylsilyl group into ...

2005